{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:32:38Z","timestamp":1770489158090,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi Pasteur MSD"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.vaccine.2018.10.100","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T12:00:11Z","timestamp":1542888011000},"page":"8019-8027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers"],"prefix":"10.1016","volume":"36","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Eymin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.100_b0005","series-title":"Vaccines","first-page":"388","article-title":"Meningococcal vaccines","author":"Granoff","year":"2012"},{"key":"10.1016\/j.vaccine.2018.10.100_b0010","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.100_b0015","unstructured":"European Centre for Disease Prevention and Control. European invasive bacterial disease surveillance network (EU-IBD); 2017. <https:\/\/ecdc.europa.eu\/en\/about-us\/networks\/disease-and-laboratory-networks\/eu-ibd> [accessed 09 November 2017]."},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2018.10.100_b0020","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2018.10.100_b0025","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2018.10.100_b0030","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.cmi.2016.03.006","article-title":"Can we control all-cause meningococcal disease in Europe?","volume":"22","author":"Sadarangani","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.10.100_b0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.vaccine.2016.11.053","article-title":"Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants","volume":"35","author":"Vesikari","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.100_b0040","unstructured":"European Medicines Agency. Hexyon: summary of product characteristics; 2017. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002796\/human_med_001641.jsp&mid=WC0b01ac058001d124> [accessed 09 November 2017]."},{"key":"10.1016\/j.vaccine.2018.10.100_b0045","unstructured":"European Medicines Agency. Nimenrix: summary of product characteristics; 2017. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002226\/human_med_001548.jsp&mid=WC0b01ac058001d124> [accessed 09 November 2017]."},{"key":"10.1016\/j.vaccine.2018.10.100_b0050","unstructured":"electronic Medicines Compendium (eMC). NeisVac-C: summary of product characteristics; 2017. <https:\/\/www.medicines.org.uk\/emc\/medicine\/30325> [accessed 09 November 2017]."},{"key":"10.1016\/j.vaccine.2018.10.100_b0055","unstructured":"European Medicines Agency. Prevenar 13: summary of product characteristics; 2017. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001104\/human_med_001220.jsp&mid=WC0b01ac058001d124> [accessed 09 November 2017]."},{"key":"10.1016\/j.vaccine.2018.10.100_b0060","unstructured":"European Medicines Agency. M-M-RVaxPro: summary of product characteristics; 2017. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000604\/human_med_000907.jsp&mid=WC0b01ac058001d124> [accessed 09 November 2017]."},{"key":"10.1016\/j.vaccine.2018.10.100_b0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assay","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.10.100_b0070","series-title":"5th Asian Congress of Pediatric Infectious Diseases (ACPID), Taipei, Taiwan, 23\u201326 September","article-title":"Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-HepB-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15\u201318 months compared to licensed vaccines in Turkish infants","author":"Ceyhan","year":"2010"},{"key":"10.1016\/j.vaccine.2018.10.100_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-013-0007-7","article-title":"DTaP-IPV-Hep B-Hib vaccine (Hexaxim\u00ae): a review of its use in primary and booster vaccination","volume":"15","author":"McCormack","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.vaccine.2018.10.100_b0080","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14712598.2013.774368","article-title":"Review of a new fully liquid, hexavalent vaccine: Hexaxim","volume":"13","author":"Nunes","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2018.10.100_b0085","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3906\/sag-1609-62","article-title":"A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers","volume":"47","author":"Ceyhan","year":"2017","journal-title":"Turk J Med Sci."},{"key":"10.1016\/j.vaccine.2018.10.100_b0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2018.10.100_b0095","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.100_b0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac\u2013C","volume":"8","author":"Borrow","year":"2009","journal-title":"Exp Rev Vacc"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.100_b0105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/INF.0000000000000750","article-title":"Randomized trial to compare the immunogenicity and safety of a CRM or TT conjugated quadrivalent meningococcal vaccine in teenagers who received a CRM or TT conjugated serogroup C vaccine at preschool age","volume":"34","author":"Ishola","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2018.10.100_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/INF.0000000000001358","article-title":"A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule","volume":"36","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831497X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831497X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T19:43:51Z","timestamp":1605469431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1831497X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0264410X1831497X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.100","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}